Seasoned investors are almost always on the lookout for undervalued stocks in the market for the simple reason that it can often lead to considerable long-term gains. Such socks almost always fly under the radar in the market and it is imperative for investors to figure out the stocks which may be worth looking into from that particular perspective. Here is a quick look at three stocks that may be worth looking at this point.
Kaival Brands Innovations Group (NASDAQ:KAVL) – The Kaival Brands Innovations Group stocks was one of the notable gainers yesterday as it ended up with gains of as much as 5.5% for the day. The company has been on the radar of many investors in recent times after it had managed to tie up a deal with the tobacco behemoth Phillip Morris International.
The company was in the news earlier on in the week on Monday after it announced the launch of its customized product named VEEBA in Canada. It is a launch that took the deal with Philip Morris to the next stage.
Houston Natural Resources Corporation (OTCMKTS:HNRC) stock has been soaring over the past few sessions and reached a new multi-month high. The HNRC stock has been seeing heavy buying interest as Short Stock Scanners Indicate Substantial Short Exists and the short covering is underway! The company currently has earnings per share to the tune of $0.27, energy stocks trade at a PE of 17.8. At this ratio, HNRC would be $4.80 per share.
The stock has gained a whopping 147% this week from Friday’s July 22, 2022 close. Moreover, the stock closed above the 200-Day moving average.
Safe-T Group Ltd (NASDAQ:SFET) – The next one to look into at this point among undervalued stocks is the Safe-T Group Ltd stock. The company had last been in the news back on July 18 when it announced that it had been successful in expanding its offerings through the introduction of its consumer privacy solutions product. The product is meant for Android devices.
Pressure BioSciences Inc (OTCMKTS:PBIO) – The last one to add to the list of undervalued stocks is Pressure BioSciences. The company had been in the news back on July 21 when it announced that it had signed an agreement with North Star Holdings.
As per the terms of the agreement, North Star was going to provide financial assistance towards the company’s CBD spray development project.
ImmunoPrecise Antibodies (NASDAQ: IPA) (TSXV: IPA) announced its financial results for the full year today. The total revenues for the fiscal year came in at $19.4 million, which worked out to a rise of 8.1% from the previous year. Moreover, it proved to be a record for IPA as well.
The company managed to bring in project revenues of $1.4 million and which worked out to be 9.1%. However, that was not all. It was also announced that IPA had also managed to make a strategic investment worth as much as $6.7 million through its subsidiary unit Talem Therapeutics LLC.